Pfizer’s BRAFTOVI combo doubles progression-free survival in aggressive colorectal cancer trial

The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival

Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial

This marks one of the most closely watched oncology readouts at this year’s medical congress

International scientists say deuterium research could reshape medicine

The conference highlighted research suggesting that deuterium levels may influence key biological processes

Dr. Morepen partners with VIT Bhopal to launch integrated on-campus health centre

The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide

Oval Fertility launches in Hyderabad, introduces Astec Chronos AI-powered IVF tech to India

Aims to bridge transparency gaps in fertility care, with focus on successful patient outcomes, placing healthy live birth outcomes at the centre of treatment journeys

Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%

MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease

AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia

The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,

Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial

The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer

Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting

The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial

Glenmark posts strong FY26 results with 27.5% revenue jump